参考文献 1. 《儿童抗肿瘤药物临床研发技术指导原则》. 2. US FDA Guidance
for Industry: Pediatric Study Plans:Content of and Process for Submitting
Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans; July
2020. 3. EMA: Pediatric
Investigation Plan (PIP)- Key Elements Guidance; June 2024. 4. 《儿科用药临床药理学研究技术指导原则》. 5. 《生理药代动力学模型在儿科人群药物研发中应用的技术指导原则》. 6. 《成人用药数据外推至儿科人群的定量方法学指导原则（试行）》. 7. 《真实世界研究支持儿童药物研发与审评的技术指导原则（试行）》. 8. ICH E11 (R1)
Guideline: Clinical Investigation of Medicinal Products in the Paediatric
Population; August 2017. 9. ICH E11A
Guideline: Pediatric Extrapolation; August 2024. 10. ICH S9
Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals; October 2009. 11. ICH M3
Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human
Clinical Trials and Marketing Authorization for Pharmaceuticals; June 2009. 12. Leighton,
J.K., Helms, W. (2022). An FDA Oncology Perspective of Juvenile Toxicity
Studies to Support Pediatric Drug Development. In: DiMartino, J., Reaman, G.H.,Smith,
F.O. (eds) Pediatric Cancer Therapeutics Development. Pediatric Oncology.
Springer, Cham. https://doi.org/10.1007/978-3-031-06357-2_3. 13. Barry, E.,
Walsh, J.A., Weinrich, S.L. et al. Navigating the Regulatory Landscape to
Develop Pediatric Oncology Drugs:Expert Opinion Recommendations. Pediatric
Drugs 23, 381–394 (2021). 14. 《儿童用药（化学药品）药学开发指导原则（试行）》. 15. 《儿童用化学药品改良型新药临床试验技术指导原则（试行）》. 16. 《儿童用药口感设计与评价的技术指导原则（试行）》. |
